The Society for Immunotherapy of Cancer (SITC) hosted Session 107b during the 38th Annual Meeting & Pre-Conference Programs on Friday, November 3, 2023. Available here are the presentation slides and video from “Session 107b: Promising Novel Biotechnologies for the Next Wave of IO Innovation” as permitted by presenters.
Jane Grogan, PhD – Biogen
Zhen Su, MD, MBA – Marengo Therapeutics
Over the last decade, cancer immunotherapy has revolutionized the lives of millions of people worldwide who are battling cancer. The advent of immunotherapy treatments like immune checkpoint inhibitors (ICI), T-cell engagers (TCE), and chimeric antigen receptor T-cell therapy (CAR-T) has not only transformed patient care, but also opened up new avenues for research and innovation. However, whilst transformative, current treatments are not a panacea and many tumors remain refractory to immunotherapies. They have sparked a renaissance of therapeutic discovery and have attracted multidisciplinary teams to the field, bringing with them their unique perspectives and expertise. Together, we can co-create the next wave of immunotherapy treatments and continue to push the boundaries of what's possible in the fight against cancer. In this session, we will review the rapidly evolving landscape of IO biotech and discuss some of the most promising novel approaches to unleash the full potential of anti-tumor immune response for the next wave of IO medicines.
To view the entire program schedule (including presenter permission to post) please click here.
SITC 2023 Annual Meeting: Friday, November 301:42:26